NewAmsterdam Pharma N.V. (NAMS) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Recursion Pharmaceuticals (RXRX) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 18.4% versus a loss of 31.3%. Over five years, NAMS leads with a +126.0% price change compared with -77.6% for RXRX. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.51 billion vs $2.12 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | RXRX |
|---|---|---|
| Share price | $21.49 | $3.95 |
| Market cap | $2.51B | $2.12B |
| 1-day change | -2.89% | -7.53% |
| YTD return | -36.92% | +4.40% |
| 1-year return | -31.29% | -18.36% |
| 5-year return | +126.05% | -77.57% |
| EPS (TTM) | $-2.16 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | — |
| Revenue growth (YoY) | -50.61% | — |
| Net income (latest FY) | $-203.82M | — |
| Operating margin | -1002.90% | — |
| Net margin | -905.74% | — |
| 52-week high | $42.21 | $7.18 |
| 52-week low | $21.02 | $2.77 |
| Distance from 52-week high | -49.08% | -45.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +131.04% | +82.84% |
| Average volume | 1.35M | 20.56M |
| Shares outstanding | 116.90M | 535.34M |
| Employees | 100 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RXRX has outperformed NAMS by 12.9 percentage points over the past year.
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
NAMS vs RXRX FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Recursion Pharmaceuticals?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.51B compared with $2.12B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, NAMS or RXRX?
RXRX returned -18.36% over the past 12 months, compared with -31.29% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for NewAmsterdam Pharma N.V. and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.